| Online-Ressource |
Verfasst von: | Möhler, Thomas [VerfasserIn]  |
| Neben, Kai [VerfasserIn]  |
| Benner, Axel [VerfasserIn]  |
| Egerer, Gerlinde [VerfasserIn]  |
| Krasniqi, Fatime [VerfasserIn]  |
| Ho, Anthony Dick [VerfasserIn]  |
| Goldschmidt, Hartmut [VerfasserIn]  |
Titel: | Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy |
Verf.angabe: | Thomas M. Moehler, Kai Neben, Axel Benner, Gerlinde Egerer, Fatime Krasniqi, Anthony D. Ho, and Hartmut Goldschmidt |
E-Jahr: | 2001 |
Jahr: | [December 15, 2001] |
Umfang: | 3 S. |
Illustrationen: | Diagramme |
Fussnoten: | Gesehen am 01.03.2022 |
Titel Quelle: | Enthalten in: Blood |
Ort Quelle: | Washington, DC : American Society of Hematology, 1946 |
Jahr Quelle: | 2001 |
Band/Heft Quelle: | 98(2001), 13 vom: Dez., Seite 3846-3848 |
ISSN Quelle: | 1528-0020 |
Abstract: | The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma. Of 50 patients evaluable for response, 4% achieved complete response (CR), 64% partial response (PR), 18% minimal response (MR), 6% stable disease (SD), and 8% progressive disease (PD), resulting in an objective response rate (≥ MR) of 86.0% (76.7% overall objective response rate in intent-to-treat analysis; n = 56). Subsequent to successful remission induction, 18 patients received autologous or allogeneic stem cell transplantation. The median progression-free survival in all patients was 16 months. The median overall survival time could not be calculated, since the last observed death occurred after 16 months of follow-up (median follow-up of 14 months) with a corresponding estimated survival probability of 55%. Severe adverse effects (World Health Organization III/IV) included infectious complications (35.7%) and cardiovascular events (7.1%). The data suggest that Thal improves antitumor activity of salvage chemotherapy regimens in poor-prognosis multiple myeloma. |
DOI: | doi:10.1182/blood.V98.13.3846 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1182/blood.V98.13.3846 |
| DOI: https://doi.org/10.1182/blood.V98.13.3846 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1794145176 |
Verknüpfungen: | → Zeitschrift |
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy / Möhler, Thomas [VerfasserIn]; [December 15, 2001] (Online-Ressource)